Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This updated guideline from the Endocrine Society highlights the importance of endocrinologists in providing safe and effective hormone regimens for gender-affirming care, especially for adolescents who have entered puberty.

This study found that human scalp hair follicles can respond to corticotropin releasing hormone stimulation similarly to the classical HPA axis, including up-regulating cortisol production and activating neuroendocrine feedback loops.

This study reported that treatment with gonadotropin-releasing hormone analogs and cross-sex hormones appears appropriate for carefully selected youth with gender dysphoria, but long-term safety needs further investigation.

This review discusses the therapeutic options for transgender individuals, including hormonal and surgical treatments, and reports no new clinical results; the authors highlight the need for more research on long-term effects.

In this study, transgender adolescents treated with testosterone for a median of 12 months experienced effective virilization, including voice deepening and increased hair growth, but also showed decreased HDL cholesterol and BMD z-scores, and increased hematocrit, with no short-term safety issues reported.

This article discusses the potential role of a local skin POMC system in the murine hair cycle and cutaneous stress responses, with no new results presented.

This review discusses how the CRH/POMC systems may regulate human hair follicle pigmentation and highlights the concept of "self-similarity" in melanocortin systems at both local and systemic levels, without presenting new experimental results.

This review discusses the various causes of hirsutism other than PCOS, emphasizing the importance of distinguishing potentially life-threatening conditions like androgen-secreting tumors from more benign causes; it reports no new clinical findings.

This review examined various treatments for hirsutism and found low to very low quality evidence suggesting that flutamide and spironolactone may help reduce hair growth, while metformin was ineffective.

This review found moderate to very low-quality evidence that spironolactone, flutamide, and cyproterone acetate combined with oral contraceptives may reduce hirsutism more effectively than placebo or metformin, though results vary among other treatments.

This review covers various treatments for managing PCOS symptoms and infertility, noting that aromatase inhibitors may be as or more effective than clomiphene citrate for ovulation induction but reports no new clinical results.

This review discusses treatment options for hirsutism in women of childbearing age, focusing on the use of contraceptives, CPA, spironolactone, and third-line therapies, and reports no clinical results.

In this study, most women with hirsutism and regular menstrual cycles were diagnosed with polycystic ovary syndrome, suggesting limited use of the term 'idiopathic or racial' hirsutism without thorough evaluation.

This article discusses various diagnostic categories and treatments for hyperandrogenism, with a focus on polycystic ovary syndrome and reports no new clinical findings, calling for specific treatments and lifestyle changes.

This study found that treatment with the GnRH agonist Triptorelin significantly decreased invasion and expression of S100A4 and CYR61 in certain breast cancer cells, suggesting a potential role in slowing cancer progression.

This abstract describes the components found in the alpha and dense granules of platelets, but it provides no new research findings.

This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.

This review discusses current treatment options for hirsutism, emphasizing the importance of combining therapies for better outcomes, but reports no new clinical findings.

TSH influences keratin expression in human hair follicles.

This review explores the evaluation and treatment of hirsutism, emphasizing a systematic approach to uncovering its causes and recommending combination therapies for effective management, but presents no new results.

This study reported that cortisone, testosterone, and thyroxine replacement therapy increased energy and hair growth, while decreasing cold sensitivity, in the absence of tumor recurrence.

This study found that human hair follicles can function like a peripheral hypothalamic-pituitary-adrenal axis, synthesizing cortisol in response to corticotropin-releasing hormone and adrenocorticotropic hormone stimulation.

This study observed that medical castration for prostate cancer prolongs the QT/QTc intervals, potentially leading to serious arrhythmias like torsade de pointes and ventricular fibrillation, even in patients without prior QT prolongation risk.

This study found that oral contraceptive pills improve mild hirsutism, while flutamide and spironolactone are beneficial for more severe cases, but other therapies show inconsistent or no benefit.

This article discusses the pathophysiology and treatment of polycystic ovary syndrome and reports no new results, emphasizing the higher risk of metabolic and cardiovascular issues for affected women.

Polycystic Ovary Syndrome (PCOS) often leads to severe acne, and lifestyle changes and hormonal treatments can help manage it.

This article reviews the physiology, causes, and treatments of hirsutism and reports no new research findings.

This review discusses the causes and treatment options for idiopathic hirsutism and reports that various therapies may reduce hirsutism severity and the Ferriman–Gallwey score by 35–40% after one year.

In this study, 48% of women with androgenetic alopecia showed hypothyroidism or hyperprolactinemia after TRH stimulation, suggesting these conditions may influence androgen metabolism and contribute to hair loss.

This study found that women with polycystic ovary syndrome have more pronounced metabolic alterations and higher androgen levels compared to women with eumenorrheic hyperandrogenism, suggesting EuHyperA may be a milder form of PCOS.